Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.66 |
| ▸ | MAOA | P21397 | 7/20 | 0.63 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321060 | 0.91 | MAOB (0.68) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL7345416 | 0.91 | MAOB (0.68) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL108114 | 0.89 | MAOB (0.74) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL11802724 | 0.87 | MAOB (0.72) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL107322 | 0.87 | MAOB (0.83) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL984460 | 0.84 | MAOB (0.68) | MAOBMAOATSHRRAB9ANPC1 | |
| SCHEMBL7236239 | 0.84 | MAOB (0.71) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL8112066 | 0.83 | MAOB (0.66) | MAOBMAOAFKBP1ATSHRRAB9A | |
| SCHEMBL7024761 | 0.83 | MAOB (0.66) | MAOBMAOATSHRRAB9ANPC1 | |
| SCHEMBL3078802 | 0.83 | MAOB (0.69) | MAOBMAOAFKBP1ATSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAOB 415/4885MAOA 1734/4885FKBP1A 349/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAOB 415/4885MAOA 1734/4885FKBP1A 349/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAOB 415/4885MAOA 1734/4885FKBP1A 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.